Get started
Author

Yutaka Susuta

Observed names: Susuta, Yutaka, Y. Susuta, Yutaka SUSUTA
Observed institution: Tanabe Pharma Corporation (Japan)
ORCID: 0000-0003-1621-9261
Observed ORCID: 0000-0003-1621-9261
OpenAlex ID: A5060684644
Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled, 12‐week study
2013 · N. Inagaki, K. Kondo, et al. · Diabetes Obesity and Metabolism · 141
PDF
Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study
2014 · Nobuya Inagaki, Kazuoki Kondo, et al. · Expert Opinion on Pharmacotherapy · 129
Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Canagliflozin for Heart Failure With Preserved Ejection Fraction in Patients With Type 2 Diabetes
2021 · Tomoya Ueda, Shu Kasama, et al. · Circulation Reports · 38
PDF
Physician–patient communication affects patient satisfaction in treatment decision-making: a structural equation modelling analysis of a web-based survey in patients with ulcerative colitis
2021 · Katsuyoshi Matsuoka, Hirono Ishikawa, et al. · Journal of Gastroenterology · 26
PDF
4. Safety Risk Evaluation Methodology in Detecting the Medicine Concomitant Use Risk which might Cause Critical Drug Rash
2014 · Yutaka SUSUTA, Yukio TAKAHASHI · Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku · 25
PDF
Amiselimod, a sphingosine 1-phosphate receptor-1 modulator, for systemic lupus erythematosus: A multicenter, open-label exploratory study
2020 · Yoshiya Tanaka, Kazuoki Kondo, et al. · Lupus · 20
PDF
Efficacy and safety of valbenazine in Japanese patients with tardive dyskinesia: A multicenter, randomized, double‐blind, placebo‐controlled study ( J‐KINECT )
2022 · Jun Horiguchi, Koichiro Watanabe, et al. · Psychiatry and Clinical Neurosciences · 15
PDF
Real-World Safety and Effectiveness of Infliximab in 255 Patients with Intestinal, Neurological, and Vascular Behçet’s Disease: A Post-Marketing Surveillance
2024 · Toshifumi Hibi, Shunsei Hirohata, et al. · Advances in Therapy · 12
PDF
Double-blind placebo-controlled study of bepotastine besilate in pediatric patients with perennial allergic rhinitis
2015 · Kimihiro Okubo, Masahiko Ichimura, et al. · Expert Opinion on Pharmacotherapy · 9
Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan
2019 · Hitoshi Tajiri, Katsuhiro Arai, et al. · BMC Pediatrics · 8
PDF
Rationale and Design of the CANONICAL Study ― Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Canagliflozin for Heart Failure With Preserved Ejection Fraction With Type 2 Diabetes Mellitus ―
2019 · Shu Kasama, Tohru Masuyama, et al. · Circulation Reports · 8
PDF
Infliximab for pediatric patients with Crohn’s disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan
2018 · Hitoshi Tajiri, Satoshi Motoya, et al. · PLoS ONE · 7
PDF
Efficacy and Safety of Valbenazine in Elderly and Nonelderly Japanese Patients With Tardive Dyskinesia: A Post Hoc Analysis of the J-KINECT Study
2024 · Yumi Watanabe, Yutaka Susuta, et al. · Journal of Clinical Psychopharmacology · 3
Safety and effectiveness of fingolimod in Japanese patients with multiple sclerosis: Results of a post‐marketing surveillance study
2024 · Noriko Sato, Koji Wakimoto, et al. · Clinical and Experimental Neuroimmunology · 2
PDF
Efficacy and Safety of Valbenazine in Japanese Patients With Tardive Dyskinesia and Schizophrenia/Schizoaffective Disorder or Bipolar Disorder/Depressive Disorder: Primary Results and Post Hoc Analyses of the J-KINECT Study
2024 · Mieko Nagano, Yutaka Susuta, et al. · Journal of Clinical Psychopharmacology · 2
Factors Predicting the Efficacy of Valbenazine and Exacerbation of Tardive Dyskinesia After Valbenazine Discontinuation in Japanese Patients: A Post Hoc Analysis of the J-KINECT Study
2025 · Yumi Watanabe, Yutaka Susuta, et al. · Journal of Clinical Psychopharmacology
Post-Marketing Surveillance Report of Rupatadine Fumarate for the Treatment of Allergic Rhinitis
2023 · Kimihiro Ohkubo, Kazuya Hirata, et al. · Practica Oto-Rhino-Laryngologica
Post-Marketing Surveillance Report of Rupatadine Fumarate for the Treatment of Urticaria and Pruritus Associated with Skin Diseases
2022 · Michihiro HIDE, Naruyasu KOMORITA, et al. · The Nishinihon Journal of Dermatology
Correction: Infliximab for pediatric patients with Crohn’s disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan
2022 · Hitoshi Tajiri, Satoshi Motoya, et al. · PLoS ONE
PDF
Phase III study of bepotastine besilate in children with atopic dermatitis-A randomized, double-blind, parallel-group, comparative study with ketotifen fumarate dry syrup-
2015 · Makoto Kawashima, Masahiko Ichimura, et al. · 臨床医薬
Works count: 22
Citation count: 445
H-index: 9
I10-index: 8
Year
Topic
Type